UBS Remains a Hold on Bayer (0P6S)
In a report released yesterday, Matthew Weston from UBS maintained a Hold rating on Bayer, with a price target of €32.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Weston is a 4-star analyst with an average return of 11.6% and an 81.05% success rate. Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and GlaxoSmithKline.
In addition to UBS, Bayer also received a Hold from TipRanks – Google’s Google General GB in a report issued on February 3. However, yesterday, Goldman Sachs maintained a Buy rating on Bayer (LSE: 0P6S).
0P6S market cap is currently €44.36B and has a P/E ratio of -222.41.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bristol Myers price target raised to $68 from $64 at BofA
- Truist incrementally positive on Bristol Myers after Bayer asundexian data
- Bayer says Asundexian showed 26% reduction in stroke in Phase III study
- Bayer investing over C$45M to build canola research, development facility
- Bayer, Vanderbilt University Medical Center enter five-year collaboration
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.